These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22908277)

  • 1. Low-level p53 expression changes transactivation rules and reveals superactivating sequences.
    Jordan JJ; Menendez D; Sharav J; Beno I; Rosenthal K; Resnick MA; Haran TE
    Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14387-92. PubMed ID: 22908277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
    Jordan JJ; Menendez D; Inga A; Noureddine M; Bell DA; Resnick MA
    PLoS Genet; 2008 Jun; 4(6):e1000104. PubMed ID: 18714371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.
    Inga A; Storici F; Darden TA; Resnick MA
    Mol Cell Biol; 2002 Dec; 22(24):8612-25. PubMed ID: 12446780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transactivation by low and high levels of human p53 reveals new physical rules of engagement and novel super-transactivation sequences.
    Menendez D; Resnick MA; Haran T
    Cell Cycle; 2012 Dec; 11(23):4287-8. PubMed ID: 23095671
    [No Abstract]   [Full Text] [Related]  

  • 6. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.
    Tomso DJ; Inga A; Menendez D; Pittman GS; Campbell MR; Storici F; Bell DA; Resnick MA
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6431-6. PubMed ID: 15843459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation.
    Su D; Wang X; Campbell MR; Song L; Safi A; Crawford GE; Bell DA
    PLoS Genet; 2015 Jan; 11(1):e1004885. PubMed ID: 25569532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.
    Menendez D; Inga A; Resnick MA
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1500-5. PubMed ID: 20080630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis.
    Nelson V; Davis GE; Maxwell SA
    Apoptosis; 2001 Jun; 6(3):221-34. PubMed ID: 11388671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p73, like its p53 homolog, shows preference for inverted repeats forming cruciforms.
    Čechová J; Coufal J; Jagelská EB; Fojta M; Brázda V
    PLoS One; 2018; 13(4):e0195835. PubMed ID: 29668749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain.
    Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S
    Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGB1-mediated DNA bending: Distinct roles in increasing p53 binding to DNA and the transactivation of p53-responsive gene promoters.
    Štros M; Kučírek M; Sani SA; Polanská E
    Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):200-210. PubMed ID: 29421308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53-dependent down-regulation of telomerase is mediated by p21waf1.
    Shats I; Milyavsky M; Tang X; Stambolsky P; Erez N; Brosh R; Kogan I; Braunstein I; Tzukerman M; Ginsberg D; Rotter V
    J Biol Chem; 2004 Dec; 279(49):50976-85. PubMed ID: 15371422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein.
    Chang J; Kim DH; Lee SW; Choi KY; Sung YC
    J Biol Chem; 1995 Oct; 270(42):25014-9. PubMed ID: 7559631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
    Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
    Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation.
    Miao L; Song Z; Jin L; Zhu YM; Wen LP; Wu M
    Oncogene; 2010 Feb; 29(5):711-22. PubMed ID: 19901969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.